[Efficacies of sorafenib plus interferon in advanced renal cell carcinoma: a report of 57 cases].

Abstract

OBJECTIVE:

To explore the efficacies and adverse events of sorafenib in the treatment of advanced metastatic renal cell carcinoma.

METHODS:

A total of 57 patients with advanced kidney cancer were recruited from our hospital from April 2007 to October 2011. They were divided into sorafenib group (A, n = 24) and sorafenib + IFN group (B, n = 33). The primary endpoints included objective response rate and progression-free survival (PFS). And the secondary endpoints were overall survival (OS) and incidence of adverse events.

RESULTS:

The mean medication time of group A was 15 (7-56) months. The outcomes were partial response (PR, n = 1), stable disease (SD, n = 8), progressive disease (PD, n = 1) and death (n = 14). The rates of objective response and disease control were 4.2% (1/24) and 37.5% (9/24) respectively. For group B, the mean medication time was 15 (4-30) months. The outcomes were PR (n = 2), and include 2 patients of PR, 21 examples of SD, 1 patient of PD and death. The rates of objective response and disease control were 6.1% (2/33) and 69.7% (23/33) respectively. Two groups had no significant difference in incidence or severity of adverse events (both P > 0.05).

CONCLUSIONS:

As a safe and effective agent for advanced kidney cancer, sorafenib is well-tolerated in patients. The combined use of interferon may improve the therapeutic efficacies without an occurrence of adverse events.

• Authors: Tao Huang, Xi-shuang Song, Zhi-wei Zhang
• Journal: Zhonghua yi xue za zhi (Zhonghua Yi Xue Za Zhi) Vol. 93 Issue 24 Pg. 1903-5 (Jun 25 2013) ISSN: 0376-2491 [Print] China
• PMID: 24124745 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Phenylurea Compounds
• Niacinamide
• Interferons
• Sorafenib

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Female
• Humans
• Interferons (administration & dosage)
• Kidney Neoplasms (drug therapy)
• Male
• Middle Aged
• Niacinamide (administration & dosage, analogs & derivatives)
• Phenylurea Compounds (administration & dosage)
• Sorafenib
• Treatment Outcome